Myelodysplastic Syndrome
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS with IPSS-R Very Low-, Low- or Intermediate-risk Who Require RBC Transfusions (MAXILUS) (CA056-1060)
- Details
ClinicalTrials.gov ID:
NCT06045689
Diagnosis Type:
NA
USOR Number:
- Address
,
P: